Ann: Updated Appendix 4C, page-90

What's the carrot for the CR? MM's cryptic C14 may get a carrot, but neither C14 nor Biotron ceos are anymore of any trust and cedibility.
MM's business is fully outsourced business. Until they secure deal, all patents and ... are just considered fake. Nobody will participate in the CR, not even the undertaker. MM has been found totally out of the way to mislead all. Money spent on Animal model just got drained, and she did not find any party to monetise the animal model. Animal model mentioned by MM as success is totally rubbish because it wasted money and did not get any money into the company. MM has mentioned data in hand while , but has the data been used to receive cash into the company from any partner. Until any cash, all are rubbish! Are MM's claims true at all anymore? They are no focused, but where are deadlines, how many approached so far, where is the comment from C14 and how long will it take? Sometime C14 means complete in 14 weeks, 14 months, 14 years. If 14 months, who will keep the biotron afloat? What are paymet structures for C14, C also means Cash first and then wait for the outcome. Has MM already paid C14? Has C14 done something so far?


C14 will work with Biotron to refine its commercialisation strategy and provide business development
support over coming months. The project and retainer fees together with an outcome-based success
component aligns the interests of the parties in achieving one or more commercial outcomes There should have been some follow-up becasue they have discussed upto their aligment of the interests. Should the SHs not get updated of the payments structures to C14 and interests of both parties? As for Business development support, what are they going to do business with - are there any product to be made available in the market. Are the things achieved in 2024 are the same as those of 2018 or better than those of 2018? The keywords coming months are misleading! Why did the C14 not give any update on timeline? Is C14 at all working with Biotron?



Michelle Miller, Biotron’s Managing Director, said: “We are delighted to be partnering with C14.
Martina and her team have a long track record in assisting companies such as Biotron to achieve
commercialisation of clinical and preclinical assets as well as platform technologies. Their involvement
allows us to leverage internal expertise in a cost-effective, efficient manner. With data from the recent
clinical trials in hand, together with supporting preclinical and scientific data that demonstrate the
potential utility of Biotron’s unique approach to treating serious viral infections, the Company is now
focused on achieving licencing or partnerships with its antiviral portfolio.” What the evidence of their track record? Have some parties become convinced with the potential utility of Biotron’s unique approach....Is C14 convinced to carry out the MM-initated discussion to final stage and get a deal done? For business purpose, C14 should have made its previous accomplished deals. Transparent Comments from the C14 and visibility of the C14's works or accomplished deals so far would make it business sense. One would consider MM low porfile and l!ar until one or more commercial outcomes become concretely public and get money into the company.